Home/Filings/4/0001628280-25-052361
4//SEC Filing

Schaeffer Orlov S Nicole 4

Accession 0001628280-25-052361

CIK 0001104506other

Filed

Nov 13, 7:00 PM ET

Accepted

Nov 14, 4:12 PM ET

Size

13.9 KB

Accession

0001628280-25-052361

Insider Transaction Report

Form 4
Period: 2025-11-12
Schaeffer Orlov S Nicole
Chief People Strategy Officer
Transactions
  • Sale

    Common Stock

    2025-11-12$192.45/sh4,078$784,81162,383 total
  • Sale

    Common Stock

    2025-11-12$193.64/sh6,575$1,273,18355,808 total
  • Sale

    Common Stock

    2025-11-12$194.44/sh19,183$3,729,94336,625 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2025-11-1230,00015,760 total
    Exercise: $26.46Exp: 2031-05-12Common Stock (30,000 underlying)
  • Sale

    Common Stock

    2025-11-12$195.88/sh164$32,12436,461 total
  • Exercise/Conversion

    Common Stock

    2025-11-12$26.46/sh+30,000$793,80066,461 total
Footnotes (5)
  • [F1]This is the weighted average sales price representing 4,078 shares sold at prices ranging from $192.00 to $192.95 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
  • [F2]This is the weighted average sales price representing 6,575 shares sold at prices ranging from $193.02 to $194.01 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
  • [F3]This is the weighted average sales price representing 19,183 shares sold at prices ranging from $194.02 to $194.95 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
  • [F4]This is the weighted average sales price representing 164 shares sold at prices ranging from $195.42 to $195.96 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
  • [F5]The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable.

Issuer

INSMED Inc

CIK 0001104506

Entity typeother

Related Parties

1
  • filerCIK 0001401017

Filing Metadata

Form type
4
Filed
Nov 13, 7:00 PM ET
Accepted
Nov 14, 4:12 PM ET
Size
13.9 KB